1
|
Heshmati Aghda N, Abdulsahib SM, Severson C, Lara EJ, Torres Hurtado S, Yildiz T, Castillo JA, Tunnell JW, Betancourt T. Induction of immunogenic cell death of cancer cells through nanoparticle-mediated dual chemotherapy and photothermal therapy. Int J Pharm 2020; 589:119787. [PMID: 32898630 DOI: 10.1016/j.ijpharm.2020.119787] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Revised: 08/11/2020] [Accepted: 08/16/2020] [Indexed: 12/18/2022]
Abstract
The use of nanomedicines to induce immunogenic cell death is a new strategy that aims to increase tumor immunogenicity and thereby prime tumors for further immunotherapies. In this study, we developed a nanoparticle formulation for combinatory chemotherapy and photothermal therapy based only on materials previously used in FDA-approved products and investigated the effect of the combinatory therapy on the growth inhibition and induction of immunogenic cell death in human MDA-MB-231 breast cancer cells. The formulation consists of ~108-nm nanoparticles made of poly(lactic acid)-b-methoxy poly(ethylene glycol) which carry doxorubicin for chemotherapy and indocyanine green for photothermal therapy. A 0.3 mg/mL suspension of NPs increased the medium temperature up to 10 °C upon irradiation with an 808-nm diode laser. In vitro studies showed that combination of laser assisted indocyanine green-mediated photothermal therapy and doxorubicin-mediated chemotherapy effectively eradicated cancer cells and resulted in the highest level of damage-associated molecular pattern presentation (calreticulin, high mobility group box 1, and adenosine triphosphate) compared to the individual treatments alone. These results demonstrate that our nanoparticle-mediated combinatory approach led to the most intense immunogenic cell death when compared to individual chemotherapy or photothermal therapy, making it a potent option for future in vivo studies in combination with cancer immunotherapies.
Collapse
Affiliation(s)
- Niloofar Heshmati Aghda
- Materials Science, Engineering and Commercialization Program, Texas State University, San Marcos, TX, USA
| | - Shahad M Abdulsahib
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX, USA
| | - Carli Severson
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX, USA
| | - Emilio J Lara
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX, USA
| | - Susana Torres Hurtado
- Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA
| | - Tugba Yildiz
- Materials Science, Engineering and Commercialization Program, Texas State University, San Marcos, TX, USA
| | - Juan A Castillo
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX, USA
| | - James W Tunnell
- Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA
| | - Tania Betancourt
- Materials Science, Engineering and Commercialization Program, Texas State University, San Marcos, TX, USA; Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX, USA.
| |
Collapse
|